Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 5, 2008, Pages 1048-1052

  Papp, Eszter ^a   Gadawski, Izabella ^a   Côté, Hélène C F ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

In vitro; Long term; Lymphoblastoid cells; Stavudine; Toxicity; Zidovudine

Indexed keywords

MESSENGER RNA; MITOCHONDRIAL DNA; MITOCHONDRIAL RNA; MULTIDRUG RESISTANCE PROTEIN 1; STAVUDINE; ZIDOVUDINE;

ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE DELETION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MITOCHONDRIAL TOXICITY; OXIDATIVE STRESS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TIME;

ANTI-HIV AGENTS; DNA, MITOCHONDRIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; K562 CELLS; P-GLYCOPROTEIN; RNA; STAVUDINE; THYMIDINE; TIME FACTORS; ZIDOVUDINE;

EID: 42149172540     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn067     Document Type: Article

References (27)

1. Zuccotti GV, Ferraris G, Agostoni C et al. Zidovudine prophylaxis and perinatal HIV-1 transmission. Acta Paediatr 1999; 88: 1298.
2. Schmit JC, Weber B. Recent advances in antiretroviral therapy and HIV infection monitoring. Intervirology 1997; 40: 304-21.
3. Cote HC. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy. Antivir Ther 2005; 10 Suppl 2: M3-11.
4. Olivero OA. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 2007; 48: 215-23.
5. Hoschale D. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity. Toxicol In Vitro 2006; 20: 535-46.
6. Divi RL, Haverkos KJ, Humsi JA et al. Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to zidovudine. Environ Mol Mutagen 2007; 48: 179-89.
7. Lund KC, Peterson LL, Wallace KB. Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother 2007; 51: 2531-9.
8. Ferraresi R, Troiano L, Rossi D et al. Mitochondrial membrane potential and nucleosidic inhibitors of HIV reverse transcriptase: A cytometric approach. Mitochondrion 2004; 4: 271-8.
9. Galluzzi L, Pinti M, Troiano, L et al. Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 2005; 10: 191-5.
10. Owen A, Pirmohamed M, Khoo SH et al. Pharmacogenetics of HIV therapy. Pharmacogenet Genomics 2006; 16: 693-703.
11. Pirmohamed M, Back DJ. The pharmacogenomics of HIV therapy. Pharmacogenomics J 2001; 1: 243-53.
12. Chaillou S, Durant J, Garraffo R et al. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials 2002; 3: 493-501.
13. Gupta S, Gollapudi S. P-glycoprotein (MDR 1 gene product) in cells of the immune system: Its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993; 13: 289-301.
14. Speck RR, Yu XF, Hildreth J et al. Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis 2002; 186: 332-40.
15. Janneh O, Jones E, Chandler B et al. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007; 60: 987-93.
16. Janneh O, Owen A, Chandler B et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005; 19 2097-102.
17. Chandler B, Almond L, Ford J et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Aoquir Immune Defic Syndr 2003; 33: 551-6.
18. Weiss J, Theile D, Ketabi-Kiyanvash N et al. Inhibition of MRP1/ ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007; 35: 340-4.
19. Chappuy H, Treluyer JM, Jullien V et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 4332-6.
20. Pacifici GM. Transfer of antivirals across the human placenta. Early Hum Dev 2005; 81: 647-54.
21. Panhard X, Legrand M, Taburet AM et al. Population pharmacokinetic analysis of lamivudine, stavudine and zidavudine in controlled HIV-infected patients on HAART. Eur J Clin Pharmacol 2007; 63 1019-29.
22. Cote HC, Brumme ZL, Craib KJ et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811-20.
23. Ziemann C, Burkle A, Kahl GF et al. Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis 1999; 20: 407-14.
24. Roy KR, Arunasree KM, Dhoot A et al. C-Phycocyanin inhibits 2-acetylaminofluorene-induced expression of MDR1 in mouse macrophage cells: ROS mediated pathway determined via combination of experimental and in silico analysis. Arch Biochem Biophys 2007; 459 169-77.
25. Ott M, Gogvadze V, Orrenius S et al. Mitochondria, oxidative stress and cell death. Apoptosis 2007; 12: 913-22.
26. Sankatsing SU, Beijnen JH, Schinkel AH et al. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 2004; 48: 1073-81.
27. Meaden ER, Hoggard PG, Maher B et al. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1329-32.